INDOCO logo

Indoco Remedies Limited Stock Price

NSEI:INDOCO Community·₹23.5b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 19 Fair Values set on narratives written by author

INDOCO Share Price Performance

₹255.09
-71.81 (-21.97%)
₹380.00
Fair Value
₹255.09
-71.81 (-21.97%)
32.9% undervalued intrinsic discount
₹380.00
Fair Value
Price ₹255.09
ThewealthyinvestorbyDSAB ₹380.00
AnalystLowTarget ₹250.00
AnalystConsensusTarget ₹260.00

INDOCO Community Narratives

·
Fair Value ₹380 32.9% undervalued intrinsic discount

Indoco Remedies Will Benefit from India's Healthcare Growth

0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
·
Fair Value ₹250 2.0% overvalued intrinsic discount

US And EU Regulation Will Hamper Long-Term Profitability

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value ₹260 1.9% undervalued intrinsic discount

Regulatory Challenges And Capacity Expansion Will Reshape Future Potential

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
₹380
32.9% undervalued intrinsic discount
Profit Margin
14.76%
Future PE
22.08x
Price in 2030
₹672.4
₹250
2.0% overvalued intrinsic discount
Profit Margin
9.3%
Future PE
9.96x
Price in 2029
₹352.26
₹260
1.9% undervalued intrinsic discount
Profit Margin
10.5%
Future PE
10.32x
Price in 2028
₹377.21

Trending Discussion

Updated Narratives

INDOCO logo

Indoco Remedies Will Benefit from India's Healthcare Growth

Fair Value: ₹380 32.9% undervalued intrinsic discount
10 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
INDOCO logo

INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook

Fair Value: ₹250 2.0% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
INDOCO logo

Regulatory Challenges And Capacity Expansion Will Reshape Future Potential

Fair Value: ₹260 1.9% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Good value with reasonable growth potential.

2 Risks
3 Rewards

Indoco Remedies Limited Key Details

₹18.5b

Revenue

₹5.4b

Cost of Revenue

₹13.0b

Gross Profit

₹14.0b

Other Expenses

-₹951.5m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-10.31
70.64%
-5.16%
111.1%
View Full Analysis

About INDOCO

Founded
1945
Employees
6000
CEO
Sundeep Bambolkar
WebsiteView website
www.indoco.com

Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, the company offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. Additionally, it provides contract research services, such as custom chemical synthesis of molecules and intermediates; process chemistry research and development; non-infringing process designing and scale up; and analytical method development, validation, impurity characterization, and polymorphic studies, solutions, as well as intellectual property management. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.

Recent INDOCO News & Updates

Narrative Update Jun 19

INDOCO: Ophthalmic Transfer And EU Approvals Will Shape Balanced Stock Outlook

Analysts have kept the Indoco Remedies price target steady at ₹250, citing small model tweaks to revenue growth, profit margin, and assumed future P/E that offset one another in their valuation work. What’s in the News for Indoco Remedies Indoco Remedies received EU GMP certification from the German Health Authority, Berlin, for its Oral Solid Dosage manufacturing facility, Plant III at Baddi, following an inspection conducted from April 22, 2026 to April 27, 2026.

Recent updates

No updates